Executive Team

Michael Gaisford MBA – President and CEO, Director

Over 15 years experience leading teams in marketing, strategy, and product management. Prior to Intera, Michael was Director of Marketing for Stratasys Healthcare Solutions, he oversaw global marketing programs across medical and dental markets. At Boston Scientific, led the productivity office, managed product marketing in the Electrophysiology division, and supported commercial strategic initiatives in neuromodulation, urology and endoscopy groups. Michael previously worked at Genentech, CVS/Pharmacy, and McKinsey & Company. He holds an MBA from the Tuck School of Business at Dartmouth and BS from Stanford University.

Spencer Malouf – Vice President of Sales

Over 25 years of medical and surgical device, sales, marketing, and sales management. Prior to Intera Oncology Spencer led a distributorship that specialized in Neuromodulation and Oncology (Hepatic Arterial Infusion) sales for Codman, Johnson & Johnson. His success in building and growing HAI programs in major cancer centers across the nation has given him the knowledge, sales leadership and strategic relationships that he brings to Intera Oncology. Spencer also trained and managed a national sales team for Innovative Pump Solutions, growing it from a new company to one of the top intrathecal compounding pharmacies in the nation in five years. He graduated from Texas Tech University with a BA and immediately went to work in the medical sales field.

Regulatory Affairs

Intera Oncology has engaged Heyer Regulatory Solutions LLC (HRS) for Regulatory Affairs and Regulatory Compliance. Founded in 2010, HRS provides premarket regulatory strategy and submissions as well as postmarket regulatory compliance services to the global medical device industry. Founder and President Sheila Hemeon-Heyer has over 30 years experience beginning at FDA where she was a Scientific Reviewer in the CDRH Office of Device Evaluation, as Director of Regulatory Services for Medical Device Consultants, Inc. (MDCI), and as Vice President, Global Regulatory Affairs for Boston Scientific Corporation. She holds a B.S. in Biomedical Engineering from Boston University, an M.S. in Biomechanics from the University of Massachusetts at Amherst, a J.D. from Western New England College School of Law, is US and EU Regulatory Affairs Certified and is a Fellow of the Regulatory Affairs Professional Society.


David Dove, MD MBA – Chairman

Dr. Dove has extensive experience in healthcare and leading development stage life science companies. Previously, Dr. Dove was President and CEO of Aeris Therapeutics, which developed and commercialized a treatment for patients with advanced emphysema. Dr. Dove also served as President and CEO of Celadon Science (aka Advanced BioHealing), a biotechnology company focused on skin and wound healing, and as President and CEO of TEI Biosciences, a regenerative medicine company. Dr. Dove received an M.D. degree from New York University and an MBA from the Haas School of Business at Berkeley and a BA in Cell Biology from Middlebury College

Jonathan Reis, MD MBA – Director

President & CEO of Censa Pharmaceuticals. Over 25 years of executive management in the life science industry, President of Cardioresponse, VP Coordinated Care Solutions, Managing Partner of Extera, Managing Director & Head Life Sciences at Armory Securities, Board Member of Janus Biotherapeutics, Atacama Therapeutics & Acer Therapeutics, and multiple corporate development roles with small to midsize life science companies. Jonathan earned his MD from Technion Institute of Technology and his MBA from Harvard Business School.

Joseph Baron MBA – Director

Joseph has extensive experience in the pharmaceutical industry as CEO of Janus Biotherapeutics, CEO of Atacama Therapeutics, Partner at Extera Partners, SVP of Corporate Development at BioAssets, member of the M&A Team at Millennium Pharmaceuticals, and Consultant for Booz Allen.